ArticlePakistan journal of medical sciences2026
Construction of a ubiquitination-related gene signature to predict prognosis and treatment response in lung adenocarcinoma.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: The prognosis of lung adenocarcinoma (LUAD) remains poor, primarily due to treatment resistance and a lack of effective biomarkers. This research investigated the potential of ubiquitination-related genes (UbRG) as prognostic indicators for LUAD. Methodology: This study was conducted at Tianjin Medical University Cancer Institute and Hospital from May 2025 to October 2025. Leveraging data from TCGA, we initially employed WGCNA to identify key modules of UbRG associated with LUAD. Then, a multigene prognostic signature was developed. To investigate the mechanisms, GSEA and CIBERSORT were used to detect activated signaling pathways and immune landscape, respectively. Finally, drug sensitivity analysis was performed. Results: Our analysis identified nine gene pairs that constitute the UbRG prognostic signature, with individuals in the high-risk cohort generally experiencing worse outcomes. Pathway enrichment analyses revealed immune response pathways in the low-risk cohort and the cell cycle and DNA replication pathways in the high-risk cohort. CIBERSORT revealed distinct immune cell distributions, with more CD4 Conclusion: This study presents a novel UbRG signature for LUAD prognosis, emphasizing the role of ubiquitination in the immune response. These findings may guide future therapeutic strategies in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.